Drug Profile
Research programme: anti-MUC1 monoclonal antibodies - Vaxil Biotherapeutics
Alternative Names: Anti-MUC1 SP vaccine companion diagnostic - Vaxil Biotherapeutics; Anti-MUC1 therapeutic cancer vaccine companion diagnostic - Vaxil BioTherapeutics; ImMucin™ companion diagnostic - Vaxil BioTherapeutics; MUC1 companion diagnostic - Vaxil BioTherapeutics; SPmAb 2.1; SPmAb 6Latest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Vaxil BioTherapeutics
- Class Monoclonal antibodies; Monoclonal antibody diagnostics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 Mar 2023 Preclinical development is ongoing (Diagnosis) for Cancer in Israel (Vaxil Biotherapeutics pipeline, March 2023)
- 24 Mar 2023 Preclinical development is ongoing for Cancer in Israel (Vaxil Biotherapeutics pipeline, March 2023)
- 01 Feb 2021 Vaxil BioTherapeutics has patent protection for anticancer antibody platform in Europe